X0202 SCHEDULE 13D/A 0001214659-24-016381 0001232621 XXXXXXXX LIVE 3 Common Shares, no par value 03/23/2026 false 0001600620 05156V102 Aurinia Pharmaceuticals Inc.

#140, 14315 - 118 Avenue Edmonton A0 T5L 4S6

Kevin Tang 858-200-3830 4747 Executive Drive Suite 210 San Diego CA 92121 0001232621 N TANG CAPITAL MANAGEMENT, LLC WC N DE 0.00 12229500.00 0.00 12229500.00 12229500.00 N 9.2 OO Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI") and Kevin Tang. The percentages used herein are based on 132,970,979 Common Shares outstanding as of February 25, 2026, as set forth in the Issuer's Annual Report filed on Form 10-K that was filed with the Securities and Exchange Commission on February 26, 2026. 0001178579 N KEVIN TANG WC N X1 0.00 12229500.00 0.00 12229500.00 12229500.00 N 9.2 IN Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, and TCM. 0001191935 N TANG CAPITAL PARTNERS, LP WC N DE 0.00 6990461.00 0.00 6990461.00 6990461.00 N 5.3 PN TCP shares voting and dispositive power over such shares with TCM and Kevin Tang. Y TANG CAPITAL PARTNERS INTERNATIONAL, LP WC N DE 0.00 5239039.00 0.00 5239039.00 5239039.00 N 3.9 PN TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang. Y TANG CAPITAL PARTNERS III, INC WC N NV 0.00 0.00 0.00 0.00 0.00 N 0 CO Y TANG CAPITAL PARTNERS IV, INC WC N NV 0.00 0.00 0.00 0.00 0.00 N 0 CO Common Shares, no par value Aurinia Pharmaceuticals Inc. #140, 14315 - 118 Avenue Edmonton A0 T5L 4S6 This Schedule 13D/A (this "Statement") amends the Schedule 13D (the "Original Schedule 13D") filed on September 12, 2024, as amended on March 4, 2025 and March 3, 2026. Item 4 of the Statement is hereby amended and supplemented to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D. Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 23, 2026, Mr. Tang was appointed as Chief Executive Officer of the Issuer. TANG CAPITAL MANAGEMENT, LLC /s/ Kevin Tang 03/25/2026 KEVIN TANG /s/ Kevin Tang 03/25/2026 TANG CAPITAL PARTNERS, LP /s/ Kevin Tang 03/25/2026 TANG CAPITAL PARTNERS INTERNATIONAL, LP /s/ Kevin Tang 03/25/2026 TANG CAPITAL PARTNERS III, INC /s/ Kevin Tang 03/25/2026 TANG CAPITAL PARTNERS IV, INC /s/ Kevin Tang 03/25/2026